CenterStar Asset Management LLC bought a new stake in Petmed Express Inc (NASDAQ:PETS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,698 shares of the company’s stock, valued at approximately $169,000.

Several other hedge funds also recently bought and sold shares of PETS. Sei Investments Co. lifted its holdings in shares of Petmed Express by 50,142.9% in the third quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock valued at $117,000 after purchasing an additional 3,510 shares in the last quarter. Sterling Investment Advisors Ltd. lifted its holdings in shares of Petmed Express by 118.5% in the fourth quarter. Sterling Investment Advisors Ltd. now owns 2,950 shares of the company’s stock valued at $134,000 after purchasing an additional 1,600 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new position in shares of Petmed Express in the third quarter valued at approximately $149,000. SG Americas Securities LLC bought a new position in shares of Petmed Express in the third quarter valued at approximately $202,000. Finally, Koch Industries Inc. bought a new position in shares of Petmed Express in the second quarter valued at approximately $212,000. Institutional investors own 97.81% of the company’s stock.

Shares of Petmed Express Inc (NASDAQ PETS) opened at $42.49 on Friday. The company has a market capitalization of $875.48, a P/E ratio of 25.14, a P/E/G ratio of 2.63 and a beta of 0.95. Petmed Express Inc has a 52-week low of $19.21 and a 52-week high of $57.80.

Petmed Express (NASDAQ:PETS) last issued its quarterly earnings results on Monday, January 22nd. The company reported $0.44 EPS for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.11. The company had revenue of $60.10 million during the quarter, compared to the consensus estimate of $56.76 million. Petmed Express had a return on equity of 34.04% and a net margin of 12.84%. Petmed Express’s revenue was up 13.6% on a year-over-year basis. During the same period last year, the business posted $0.24 earnings per share. analysts predict that Petmed Express Inc will post 1.7 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 16th. Investors of record on Monday, February 5th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.35%. This is an increase from Petmed Express’s previous quarterly dividend of $0.20. The ex-dividend date is Friday, February 2nd. Petmed Express’s dividend payout ratio (DPR) is presently 59.17%.

In related news, Director Ronald J. Korn sold 5,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $48.38, for a total transaction of $241,900.00. Following the completion of the sale, the director now directly owns 68,833 shares of the company’s stock, valued at $3,330,140.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gian Fulgoni sold 20,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $44.38, for a total value of $887,600.00. Following the completion of the sale, the director now directly owns 55,900 shares of the company’s stock, valued at $2,480,842. The disclosure for this sale can be found here. Insiders have sold 65,000 shares of company stock valued at $3,229,500 over the last ninety days. 4.00% of the stock is currently owned by company insiders.

A number of research analysts have recently weighed in on PETS shares. Zacks Investment Research upgraded Petmed Express from a “sell” rating to a “hold” rating and set a $50.00 target price on the stock in a report on Friday, October 20th. Noble Financial restated a “hold” rating on shares of Petmed Express in a report on Friday, October 27th. BidaskClub raised Petmed Express from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 9th. Northcoast Research set a $58.00 price target on Petmed Express and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, ValuEngine raised Petmed Express from a “hold” rating to a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $42.80.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/09/3698-shares-in-petmed-express-inc-pets-purchased-by-centerstar-asset-management-llc.html.

Petmed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Petmed Express Inc (NASDAQ:PETS).

Institutional Ownership by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.